 Revance Therapeutics, Inc. NASDAQ:RVNC Q3 2022 Results Conference Call November 8, 2022 4:30 PM ET Company Participants Jessica Serra - Head of Investor Relations ESG Mark Foley - Chief Executive Officer Dustin Sjuts - President Tobin Schilke - Chief Financial Officer Principal Accounting Officer Conference Call Participants Chris Shibutani - Goldman Sachs Ken Cacciatore - Cowen David Amsellem - Piper Sandler Stacy Lee - Stifel Justin Phillips - Morgan Stanley Rohit Bhasin - Needham Company Operator Welcome to the Revance Therapeutics Third Quarter 2022 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. 